Skip to main content
Fig. 4 | Journal for ImmunoTherapy of Cancer

Fig. 4

From: Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies

Fig. 4

Anti-cath-D antibody-based therapy prevents macrophage recruitment within MDA-MB-231 tumor xenografts. a Tumor growth. When MDA-MB-231 tumor xenografts reached a volume of 50 mm3, nude mice were treated with F1 (n = 9), E2 (n = 9), or rituximab (CTRL; n =9) (15 mg/kg) for 28 days (day 16–44). At day 44, all mice were sacrificed. ***, P = 0.001 for F1; **, P = 0.002 for E2 (mixed-effects ML regression test). b Mean tumor volume at day 44. n = 9 for CTRL; n = 9 for F1; n = 9 for E2. ***, P = 0.0001 for F1; **, P = 0.0012 for E2 (Student’s t test); mean ± SEM. c Representative images of F4/80 immunostaining in MDA-MB-231 tumor cell xenografts from CTRL- (rituximab), F1- and E2-treated mice. Scale bars, 100 μm. d Quantification of F4/80+ macrophages. Percentage (mean ± SEM) of positive pixels relative to the total pixels; n = 9 for rituximab (CTRL); n = 9 for F1; n = 9 for E2; ***, P < 0.0001 for F1; **, P = 0.0063 for E2 (Student’s t-test). e Linear regression analysis of F4/80+ macrophages and tumor volumes. R2 = 0.1553; *, P = 0.0464, n = 27

Back to article page